ADC Therapeutics

ADC Therapeutics developed Zynlonta and the PBD-payload ADC platform.

Loncastuximab tesirine; LOTIS-5/7 combination trials; exatecan-based next-generation ADCs.

Headquarters

Lausanne, CH

Type

biotech · ADCT

Website

Products

Loncastuximab tesirine (Zynlonta) is a CD19 ADC with a DNA-crosslinking payload for relapsed large B-cell lymphoma.

not linked directly; found by shared links